domvanalimab (AB154) / Arcus Biosci, Gilead 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
domvanalimab (AB154) / Arcus Biosci, Gilead
2020-003562-39: Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung Cancer

Not yet recruiting
3
600
Europe
Zimberelimab, Domvanalimab, Carboplatin, Paclitaxel, Pemetrexed, AB122, AB154, Carboplatin, Paclitaxel, Pemetrexed, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
First Line Non-Small Cell Lung Cancer, First Line Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
2022-002222-27: A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body

Ongoing
3
970
Europe
Domvanalimab, Zimberelimab, OPDIVO, AB154, AB122, Concentrate for solution for infusion, OPDIVO
Arcus Biosciences, Inc., Arcus Biosciences Inc, Arcus Biosciences, Inc.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer, Diseases [C] - Cancer [C04]
 
 
2022-000578-25: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non–Small Cell Lung Cancer

Not yet recruiting
3
780
Europe
Zimberelimab, Domvanalimab, Pembrolizumab, GS-0122, Solution for infusion, Pembrolizumab
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, Metastatic Non–Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT04736173: Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
3
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
08/24
07/27
STAR-221, NCT05568095: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting
3
1040
Europe, Canada, Japan, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
05/26
05/26
PACIFIC-8, NCT05211895 / 2021-004327-32: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Calendar Jan 2024 - Dec 2024: Data from PACIFIC-8 trial for NSCLC
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with domvanalimab for stage 3 NSCLC (based on PACIFIC-8 trial)
Checkmark Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Mar 2022 - Mar 2022: Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Recruiting
3
860
Europe, Canada, Japan, US, RoW
Durvalumab, Domvanalimab, Placebo
AstraZeneca, Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
06/28
08/30
STAR-121, NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Recruiting
3
720
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
ZODIAC, NCT06250036: Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma

Not yet recruiting
2
50
NA
Single agent zimberelimab, Combination zimberelimab + domvanalimab
Royal Marsden NHS Foundation Trust, Gilead Sciences
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
09/26
09/31
TROPHY-U-01, NCT03547973 / 2018-001167-23: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPHY U-01 trial for metastatic urothelial cancer at ASCO 2023
Checkmark Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
Checkmark Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 study in combination with pembrolizumab for 2L metastatic urothelial cancer at ESMO 2020
More
Recruiting
2
643
Europe, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Cisplatin, Avelumab, BAVENCIO®, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab
Gilead Sciences, Merck KGaA, Darmstadt, Germany
Metastatic Urothelial Cancer
07/24
07/26
NCT06133517: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Not yet recruiting
2
70
Europe
Sacituzumab govitecan, Trodelvy, Zimberelimab, Domvanalimab
Fundación para el Progreso de la Oncología en Cantabria, Apices Soluciones S.L.
Urothelial Bladder Carcinoma
12/30
12/30
NCT04791839: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Checkmark Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Dec 2022 - Dec 2022: Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Active, not recruiting
2
30
US
Zimberelimab, Domvanalimab, Etrumadenant
Washington University School of Medicine, Arcus Biosciences, Inc.
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
01/25
04/29
NCT05130177: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Recruiting
2
26
US
Zimberelimab, AB122, Domvanalimab, AB154
Diwakar Davar, Arcus Biosciences, Inc.
Melanoma
01/27
01/30
ARC-7, NCT04262856: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Checkmark Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
May 2022 - May 2022: Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
Active, not recruiting
2
151
Canada, US, RoW
Domvanalimab, AB154, Etrumadenant, AB928, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
02/25
02/25
NCT05724563: Domvanalimab and Zimberelimab in Advanced Liver Cancers

Recruiting
2
58
US
Zimberelimab, AB122, Domvanalimab, AB154
University of Texas Southwestern Medical Center, Arcus Biosciences, Inc., Cancer Prevention Research Institute of Texas
Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
07/26
06/27
EDGE-Gastric, NCT05329766: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Calendar Jan 2023 - Dec 2024: Data from ARC-21 trial for esophageal adenocarcinoma, gastroesophageal junction and gastric adenocarcinoma
Recruiting
2
360
Europe, Canada, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc., Gilead Sciences
Gastrointestinal Tract Malignancies
09/26
06/27
EDGE-Lung, NCT05676931: Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer

Recruiting
2
320
Europe, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
Gilead Sciences, Arcus Biosciences, Inc.
Advanced Non-Small Cell Lung Cancer
09/26
09/26
VELOCITY-Lung, NCT05633667: Study of Novel Treatment Combinations in Patients With Lung Cancer

Recruiting
2
397
Europe, US, RoW
Zimberelimab (ZIM), AB122, GS-0122, Domvanalimab (DOM), AB154, GS-0154, Sacituzumab govitecan-hziy (SG), GS-0132, IMMU-132, Etrumadenant (ETRUMA), AB928, GS-0928, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Gilead Sciences, Arcus Biosciences, Inc.
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
01/27
01/27
NCT05419479: Switch Maintenance in Pancreatic

Recruiting
1/2
46
US
ZIMBERELIMAB, AB 122, DOMVANALIMAB, AB 154, APX005M, CD40, FOLFIRI
James Cleary, MD, PhD, Arcus Biosciences, Inc., Lustgarten Foundation
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
01/26
09/28
NCT03628677: A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Active, not recruiting
1
75
US, RoW
Domvanalimab, AB154, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Solid Tumor, Unspecified, Adult
11/24
11/24
NCT04656535: AB154 Combined With AB122 for Recurrent Glioblastoma

Recruiting
1
46
US
AB122, AB154, Placebo
Yale University, Arcus Biosciences, Inc., National Cancer Institute (NCI)
Glioblastoma
02/25
12/25

Download Options